NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NLSP

NLS Pharmaceutics Ltd

Jun 30 • 04:00PM ET

2.90

Dollar change +0.11
Percentage change 3.94	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: VRNA OCUL EYEN RLMD GNPX ARDX ALDX MNOV ANVS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.63	Insider Own	42.10%	Shs Outstand	3.16M	Perf Week	24.46%
Market Cap	10.43M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.08M	Perf Month	23.93%
Enterprise Value	11.50M	PEG	-	EPS next Q	-	Inst Own	4.78%	Short Float	3.48%	Perf Quarter	123.08%
Income	-4.06M	P/S	-	EPS this Y	-	Inst Trans	0.37%	Short Ratio	0.27	Perf Half Y	53.15%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-97.10%	Short Interest	0.07M	Perf YTD	37.44%
Book/sh	-0.42	P/C	6.25	EPS next 5Y	-	ROE	-	52W High	15.59 -81.40%	Perf Year	-60.30%
Cash/sh	0.46	P/FCF	-	EPS past 3/5Y	56.71% 33.06%	ROIC	-288.47%	52W Low	1.30 123.08%	Perf 3Y	-87.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.96% 9.91%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	80.67%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.69	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	70.68	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.69	EPS Q/Q	87.78%	SMA20	22.03%	Beta	0.17	Target Price	160.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	47.41%	Rel Volume	3.89	Prev Close	2.79
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	9.58%	Avg Volume	269.44K	Price	2.90
IPO	Jan 29, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	1,011,083	Change	3.94%

Jun-30-25 07:00AM	NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing (PR Newswire)
Jun-16-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
May-21-25 07:30AM	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting (PR Newswire)
Apr-15-25 09:00AM	NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire)
Mar-31-25 09:10AM	NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement (ACCESSWIRE) +18.46%
07:00AM	Loading…
Mar-10-25 07:00AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
Feb-27-25 07:00AM	NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform (PR Newswire)
Feb-25-25 09:05AM	Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment (PR Newswire)
Feb-10-25 07:30AM	NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies (PR Newswire) +37.43%
Jan-31-25 07:30AM	Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) +25.76%
Jan-30-25 07:30AM	NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting (PR Newswire)
Jan-28-25 07:30AM	NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence (PR Newswire)
Jan-16-25 09:32AM	Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire)
Jan-09-25 08:28AM	NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising (TipRanks)
Jan-08-25 07:42AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 (PR Newswire) +16.99%
07:30AM	Loading…
Dec-30-24 07:30AM	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger (PR Newswire) +49.45%
Dec-19-24 07:30AM	NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment (ACCESSWIRE) +19.00%
Dec-12-24 07:45AM	NLS Pharmaceutics expects to close Kadimastem merger by end of January (TipRanks)
Dec-11-24 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE)
Dec-04-24 01:15PM	NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market (PR Newswire)
Dec-03-24 07:40AM	NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders (ACCESSWIRE) -11.22%
Nov-18-24 07:30AM	NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders (ACCESSWIRE)
Nov-05-24 07:31AM	NLS Pharmaceutics, Kadimastem enter definitive merger agreement (TipRanks) -7.97%
Nov-04-24 07:00AM	NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement (ACCESSWIRE) +21.94%
Oct-28-24 07:00AM	NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Oct-21-24 07:00AM	NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence (ACCESSWIRE) -10.19%
Oct-19-24 04:57PM	NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges (TipRanks)
Oct-15-24 07:00AM	NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE)
Sep-25-24 08:00AM	NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split (ACCESSWIRE)
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) +23.05%
07:00AM	Loading…
07:00AM	NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge (ACCESSWIRE)
Jun-28-24 09:00AM	NLS Pharmaceutics Announces Registered Direct Offering (ACCESSWIRE) -9.63%
Jun-27-24 08:00AM	NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments (ACCESSWIRE) +31.43%
Jun-25-24 08:30AM	Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements (ACCESSWIRE) -5.61%
Jun-20-24 09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace) -30.80%
08:38AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 07:54AM	Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today? (InvestorPlace) +82.13%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-11-24 08:30AM	NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) (ACCESSWIRE) +6.33%
May-28-24 08:00AM	NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model (ACCESSWIRE)
May-24-24 05:00PM	NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq (ACCESSWIRE)
Apr-19-24 05:00PM	NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing (ACCESSWIRE)
Mar-22-24 04:30PM	NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering (ACCESSWIRE) +5.94% -8.06%
Mar-20-24 01:40PM	NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering (ACCESSWIRE) -41.72%
07:30AM	NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform (ACCESSWIRE)
Mar-14-24 08:00AM	NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event (ACCESSWIRE)
Mar-11-24 07:00AM	Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance (ACCESSWIRE) +8.97%
Feb-23-24 07:30AM	NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq (ACCESSWIRE)
Jan-12-24 04:30PM	Notice of Deficiency with Nasdaq Continued Listing Requirements (ACCESSWIRE) -7.88%
Dec-29-23 04:30PM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +16.60%
Dec-04-23 09:06AM	Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today? (InvestorPlace) -8.20%
07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 07:30AM	NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. (ACCESSWIRE) +45.27%
Nov-28-23 07:30AM	NLS Pharmaceutics Announces Election of Additional Board Members (ACCESSWIRE)
Nov-27-23 08:30AM	NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia (ACCESSWIRE)
Nov-16-23 08:00AM	NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan (ACCESSWIRE) -34.44%
Oct-25-23 04:30PM	NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification (ACCESSWIRE) -7.14%
Oct-19-23 05:00PM	NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions (ACCESSWIRE) -15.03%
Oct-12-23 09:40AM	NLS Pharmaceutics Announces Company Update on Strategic Partnerships (ACCESSWIRE) -12.63%
Aug-28-23 07:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE) +9.63%
Jul-03-23 07:00AM	NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol (ACCESSWIRE) +9.09%
Jun-30-23 04:05PM	NLS Pharmaceutics Releases the Results from its Annual General Meeting (ACCESSWIRE) +19.57%
08:00AM	NLS Pharmaceutics Company Update and Webcast Today Postponed (ACCESSWIRE)
Jun-19-23 07:30AM	CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE)
07:10AM	NLS Pharmaceutics Announces Company Update Webcast (ACCESSWIRE)
Jun-15-23 08:30AM	NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +6.01%
07:30AM	NLS Pharmaceutics Announces Company Update Webcast (ACCESSWIRE)
Jun-14-23 07:30AM	NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol (ACCESSWIRE)
May-08-23 08:30AM	NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer (ACCESSWIRE)
May-04-23 08:30AM	NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023 (ACCESSWIRE) -5.18%
May-02-23 08:45AM	NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy (ACCESSWIRE) +8.59%
Apr-25-23 08:50AM	NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology (ACCESSWIRE)
Mar-27-23 08:30AM	NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2 (ACCESSWIRE) +7.72%
Mar-01-23 08:30AM	NLS Pharmaceutics to Present at the 35th Annual Roth Conference (ACCESSWIRE)
Jan-30-23 08:30AM	NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy (ACCESSWIRE)
Jan-25-23 08:30AM	NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement (ACCESSWIRE)
Jan-23-23 08:30AM	NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity (ACCESSWIRE)
Jan-12-23 08:30AM	NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds (ACCESSWIRE)
08:15AM	NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement (ACCESSWIRE)
Jan-11-23 08:30AM	NLS Pharmaceutics to Participate in Upcoming Investor Conferences (ACCESSWIRE) +7.06%
Jan-10-23 08:30AM	NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong (ACCESSWIRE) +9.68%
Dec-22-22 08:30AM	NLS Pharmaceutics CEO Issues Letter to Shareholders (ACCESSWIRE)
Dec-20-22 09:05AM	NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037 (ACCESSWIRE)
Dec-14-22 08:30AM	NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P. (ACCESSWIRE) +5.26%
Dec-07-22 08:25AM	NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification (ACCESSWIRE)
08:25AM	NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million (ACCESSWIRE)
Dec-01-22 08:00AM	NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder (ACCESSWIRE)
Nov-23-22 08:30AM	NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe (ACCESSWIRE) +28.57%
Nov-14-22 08:30AM	NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice (ACCESSWIRE) +8.00%
Nov-07-22 08:45AM	NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy (ACCESSWIRE) +8.73%
Nov-02-22 10:40AM	U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH) (ACCESSWIRE) -17.30%
Oct-05-22 04:30PM	NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing (ACCESSWIRE) +5.24% -9.67%
Oct-03-22 08:30AM	NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes (ACCESSWIRE) +18.11%
Sep-27-22 12:02PM	NLS Pharmaceutics' Shares Fall As Data From Narcolepsy Candidate Fails To Cheer Investors (Benzinga) -25.07%
08:00AM	NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy (ACCESSWIRE)
Sep-19-22 08:00AM	NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results (ACCESSWIRE)
Sep-08-22 08:00AM	NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development (ACCESSWIRE) +14.74%
Jul-28-22 08:30AM	NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release (ACCESSWIRE) +9.07%
Jul-21-22 08:30AM	NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia (ACCESSWIRE) -31.08%

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NLSP

NLS Pharmaceutics Ltd

Upgrade your FINVIZ experience